
Results
14
Companies which are more than 50% undervalued based on analyst price target.
14 companies
Inventiva
Market Cap: €881.3m
A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.
IVA
€3.75
7D
9.7%
1Y
37.2%
Valneva
Market Cap: €413.2m
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
VLA
€2.27
7D
-1.7%
1Y
-13.2%
Cellectis
Market Cap: €188.0m
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
ALCLS
€2.54
7D
-9.9%
1Y
53.1%
Innate Pharma
Market Cap: €147.7m
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.
IPH
€1.60
7D
-6.2%
1Y
8.8%
Sensorion
Market Cap: €133.8m
A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
ALSEN
€0.26
7D
0.8%
1Y
-14.8%
OSE Immunotherapeutics
Market Cap: €78.1m
A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.
OSE
€3.30
7D
-7.9%
1Y
-35.5%
Adocia
Market Cap: €73.2m
A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.
ADOC
€3.74
7D
-11.6%
1Y
-0.3%
ABIONYX Pharma
Market Cap: €65.4m
A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.
ABNX
€1.87
7D
-8.3%
1Y
53.3%
AB Science
Market Cap: €58.7m
A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.
AB
€0.69
7D
-8.8%
1Y
-47.9%
MaaT Pharma
Market Cap: €52.4m
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.
MAAT
€2.68
7D
-2.4%
1Y
-42.1%
Nicox
Market Cap: €33.9m
Operates as an ophthalmology company in France and internationally.
ALCOX
€0.40
7D
0.3%
1Y
74.4%
Advicenne
Market Cap: €25.8m
A specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally.
ALDVI
€1.86
7D
-15.8%
1Y
38.4%
GenSight Biologics
Market Cap: €19.3m
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
SIGHT
€0.082
7D
-1.4%
1Y
-34.0%
Valbiotis
Market Cap: €18.7m
Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.
ALVAL
€0.80
7D
-3.0%
1Y
-3.3%